Yuan Qi

Aug 30, 2024 | digitalcommons.library.tmc.edu | Chang Sun |Yuan Qi |Natalie Fowlkes |Nina Lazic

Daxx functions as a histone chaperone for the histone H3 variant, H3.3, and is essential for embryonic development. Daxx interacts with Atrx to form a protein complex that deposits H3.3 into heterochromatic regions of the genome, including centromeres, telomeres, and repeat loci.

Jul 6, 2024 | mdpi.com | Rui Yang |Yuan Qi |Hongwei Wang

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jun 5, 2024 | preprints.org | Rui Yang |Yuan Qi |Hongwei Wang

PreprintArticleVersion 1This version is not peer-reviewedVersion 1: Received: 31 May 2024 / Approved: 31 May 2024 / Online: 5 June 2024 (10:22:40 CEST)Yang, R.; Qi, Y.; Zhang, H.; Wang, H.; Zhang, J.; Ma, X.; Zhang, J.; Ma, C. Study on Object-Based High-Resolution Remote Sensing Image Classification of Crop Planting Structure in the Loess Plateau of Eastern Gansu Province. Preprints 2024, 2024052156.

May 26, 2024 | nature.com | Reid T. Powell |Amanda Rinkenbaugh |Xiaomei Zhang |Yuan Qi |Clifford Stephan |Peter J Davies | +2 more

AbstractTriple negative breast cancer (TNBC) accounts for 15–20% of breast cancer cases in the United States. Systemic neoadjuvant chemotherapy (NACT), with or without immunotherapy, is the current standard of care for patients with early-stage TNBC. However, up to 70% of TNBC patients have significant residual disease once NACT is completed, which is associated with a high risk of developing recurrence within two to three years of surgical resection.

Apr 1, 2024 | nature.com | Wei Zhou |Yuan Qi |Toshitha Kannan |Hiroaki Tateno |Daniel T. Claiborne |Mohamed Abdel-Mohsen

AbstractAberrant glycosylation is a crucial strategy employed by cancer cells to evade cellular immunity. However, it’s unclear whether homologous recombination (HR) status-dependent glycosylation can be therapeutically explored. Here, we show that the inhibition of branched N-glycans sensitizes HR-proficient, but not HR-deficient, epithelial ovarian cancers (EOCs) to immune checkpoint blockade (ICB).